Applied DNA Sciences Approves Reverse Stock Split

An announcement from Applied DNA Sciences ( (APDN) ) is now available.

On May 22, 2025, Applied DNA Sciences‘ stockholders authorized a reverse stock split at a ratio of one-for-fifteen, effective June 2, 2025. This move, aimed at meeting Nasdaq’s minimum bid price requirement, will reduce the company’s outstanding shares from approximately 7.8 million to about 0.5 million, with trading on a split-adjusted basis beginning on the effective date.

The most recent analyst rating on (APDN) stock is a Buy with a $1.50 price target. To see the full list of analyst forecasts on Applied DNA Sciences stock, see the APDN Stock Forecast page.

Spark’s Take on APDN Stock

According to Spark, TipRanks’ AI Analyst, APDN is a Neutral.

Applied DNA Sciences faces substantial financial and operational challenges, as indicated by declining revenues and net losses. Despite some positive strategic moves, such as focusing on LineaRx, the stock suffers from poor technical indicators and valuation metrics. The company’s ongoing financial struggles and the uncertainties highlighted in the earnings call contribute to a low overall stock score.

To see Spark’s full report on APDN stock, click here.

More about Applied DNA Sciences

Applied DNA Sciences is a biotechnology company specializing in PCR-based DNA technologies. It operates in two primary markets: the enzymatic manufacture of synthetic DNA for nucleic acid-based therapeutics and the detection of DNA and RNA in molecular diagnostics and genetic testing services.

Average Trading Volume: 1,410,518

Technical Sentiment Signal: Strong Sell

Current Market Cap: $3.42M

See more data about APDN stock on TipRanks’ Stock Analysis page.